Diagnosis of Lung Cancer by SHOX2 Gene Methylation Assay

被引：0
作者：
Lele Song
Haotian Yu
Yuemin Li
机构：
[1] The Chinese PLA 309 Hospital,
[2] BioChain (Beijing) Science and Technology,undefined
[3] Inc,undefined
来源：
Molecular Diagnosis & Therapy | 2015年 / 19卷
关键词：
Lung Cancer; Pleural Effusion; Positive Predictive Value; National Comprehensive Cancer Network; Malignant Pleural Effusion;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Lung cancer is the most prevalent cancer in the world. Few effective and cheap methods are available so far for early detection and screening of lung cancer. Although histological and cytological examinations are gold standards in lung cancer diagnosis, patients are always at late stages when diagnosis is confirmed. Therefore, new diagnostic methods are needed urgently to increase the early diagnostic rate, enhance the confirmed diagnostic rate, and reduce mortality. The SHOX2 gene methylation assay has become a promising option for the above purposes. It has been shown to enhance the confirmed diagnostic rate of lung cancer in several clinical trials when combined with histological or cytological assays, and has the potential to become an early diagnostic tool. This article reviews the outcome of clinical trials using the SHOX2 gene methylation assay alone or in combination with other examinations, and suggests its future applications and research directions.
引用
收藏
页码：159 / 167
页数：8
相关论文
共 123 条
  • [1] Berg CD(2007)CT screening for lung cancer N Engl J Med 356 743-744
  • [2] Aberle DR(2011)Reduced lung-cancer mortality with low-dose computed tomographic screening N Engl J Med. 365 395-409
  • [3] Aberle DR(2013)Results of initial low-dose computed tomographic screening for lung cancer N Engl J Med. 368 1980-1991
  • [4] Adams AM(2013)Results of the two incidence screenings in the National Lung Screening Trial N Engl J Med. 369 920-931
  • [5] Berg CD(2014)Cost-effectiveness of CT screening in the National Lung Screening Trial N Engl J Med. 371 1793-1802
  • [6] Church TR(2003)Performance characteristics of different modalities for diagnosis of suspected lung cancer: summary of published evidence Chest. 123 115S-128S
  • [7] Black WC(2008)Predictors of diagnostic yield in bronchoscopy: a retrospective cohort study comparing different combinations of sampling techniques BMC Pulm Med. 8 2-832
  • [8] Aberle DR(2010)SHOX2 DNA methylation is a biomarker for the diagnosis of lung cancer based on bronchial aspirates BMC Cancer. 10 600-258
  • [9] Aberle DR(2012)Performance evaluation of the DNA methylation biomarker SHOX2 for the aid in diagnosis of lung cancer based on the analysis of bronchial aspirates Int J Oncol. 40 825-1638
  • [10] DeMello S(2014)Analysis of SHOX2 methylation as an aid to cytology in lung cancer diagnosis Cancer Genomics Proteomics. 11 251-104
12345678910